April 23, 2015 The TREAT-NMD Advisory Committee for Therapeutics (TACT): An Innovative de-Risking Model to Foster Orphan Drug Development
April 20, 2015 C-Path featured in the April 16 newsletter of the Multi-Regional Clinical Trials Center at Harvard
April 15, 2015 Bring Your Own Device (BYOD): The Collection Of Electronic Patient-Reported Outcome Data
April 13, 2015 Intro to ePRO – Part II This webinar provides an overview of current ePRO data collection modes, the mode selection process, key considerations for select
April 13, 2015 Critical Path Institute Secures Regulatory Support For Skeletal Muscle Safety Biomarkers April 13, 2015 Critical Path Institute Secures Regulatory Support For Skeletal Muscle Safety Biomarkers FDA and EMA Letters of Sup
March 8, 2015 Critical Path Institute Launches New Consortium Dedicated To Duchenne Muscular Dystrophy August 3, 2015 Critical Path Institute Launches New Consortium Dedicated To Duchenne Muscular Dystrophy Tucson, Arizona – August
February 6, 2015 European Medicines Agency Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development February 6, 2015 European Medicines Agency Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development Provides maj
February 3, 2015 “International Partnership to Create Global TB Data-Sharing Platform” on p. 4 of UNITAID’s “The Market Share.”
